INSOMNIA TREATMENT MARKET ANALYSIS
Recent Developments:
In January 2022, the Food and Drug Administration (FDA) approved daridorexant (Quviviq, Idorsia Pharmaceuticals) for the treatment of insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. The FDA approval is based on an extensive clinical program that included 1854 people with insomnia at more than 160 clinical trial sites across 18 countries.
In February 2020, Merck received the U.S. Food and Drug Administration (FDA) approval for its Belsomra drug to treat insomnia in patients with mild-to-moderate Alzheimer’s disease.
In July 2019, the U.S. Food and Drug Administration (FDA) approved fexinidazole as the first all-oral treatment of the Trypanosoma brucei gambiense (Human African trypanosomiasis, sleeping sickness) in patients 6 years of age and older and weighing at least 20 kg.
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India : 
